Despite previously disappointing results, Genfit made good on earlier promises Nov. 16 when it announced that it is moving its NASH candidate into Phase III based on feedback from regulatory agencies.
The French biotech will begin an 1,800-patient late-stage trial of elafibranor (GFT505) before the end of the year in patients...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?